Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
December 20 2022 - 6:11AM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
________________
FORM
6-K
________________
REPORT
OF FOREIGN PRIVATE ISSUER
Pursuant
to Rule 13a-16 or 15d-16
of
the Securities Exchange Act of 1934
December
19, 2022
________________
NOVO
NORDISK A/S
(Exact
name of Registrant as specified in its charter)
Novo
Allé
DK-
2880, Bagsvaerd
Denmark
(Address
of principal executive offices)
________________
Indicate by check mark whether the
registrant files or will file annual reports under cover of Form 20-F or Form 40-F
Form 20-F [X] |
Form 40-F [ ] |
Indicate by check mark whether the
registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If “Yes” is marked, indicate
below the file number assigned to the registrant in connection with Rule 12g-32(b):82-________
![](https://content.edgar-online.com/edgar_conv_img/2022/12/20/0001171843-22-008112_logo.jpg)
Novo
Nordisk A/S – Share repurchase programme
Bagsværd, Denmark, 19 December 2022 – On 4 November
2022, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament
and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules").
This programme is part of the overall share repurchase programme of up to DKK 24 billion to be executed during a 12- month period beginning
2 February 2022.
Under the programme initiated 4 November 2022, Novo Nordisk will repurchase B shares for an amount up to DKK 3.8 billion in the period
from 7 November 2022 to 30 January 2023.
Since the announcement of the programme, the following transactions have been made:
|
Number
of
B
shares |
Average
purchase price |
Transaction
value,
DKK |
Accumulated, last announcement |
2,073,058 |
|
1,767,800,780 |
12 December 2022 |
78,000 |
913.45 |
71,248,749 |
13 December 2022 |
75,000 |
918.97 |
68,922,852 |
14 December 2022 |
73,554 |
931.08 |
68,484,491 |
15 December 2022 |
75,000 |
934.85 |
70,113,786 |
16 December 2022 |
74,686 |
926.42 |
69,190,900 |
Accumulated under the programme |
2,449,298 |
|
2,115,761,558 |
The details for each transaction made under the share repurchase programme
are published on novonordisk.com.
Page
2 of 2
With the transactions stated above, Novo Nordisk owns a total of 29,878,116 B shares of DKK 0.20 as treasury shares, corresponding to
1.3% of the share capital. The total amount of A and B shares in the company is 2,280,000,000 including treasury shares.
Novo Nordisk expects to repurchase B shares for an amount up to DKK 24 billion during a 12- month period beginning 2 February 2022. As
of 16 December 2022, Novo Nordisk has since 2 February 2022 repurchased a total of 28,188,930 B shares at an average share price of DKK
791.06 per B share equal to a transaction value of DKK 22,299,163,613.
Novo Nordisk is a leading global healthcare company, founded in 1923 and headquartered in Denmark. Our purpose is to drive change to defeat
diabetes and other serious chronic diseases such as obesity and rare blood and endocrine disorders. We do so by pioneering scientific
breakthroughs, expanding access to our medicines, and working to prevent and ultimately cure disease. Novo Nordisk employs about 53,000
people in 80 countries and markets its products in around 170 countries. Novo Nordisk's B shares are listed on Nasdaq Copenhagen (Novo-B).
Its ADRs are listed on the New York Stock Exchange (NVO). For more information, visit novonordisk.com, Facebook, Twitter, LinkedIn and
YouTube.
Contact for further information
Media: |
|
Ambre Brown Morley
+45 3079 9289
abmo@novonordisk.com |
Natalia Salomao Abrahao (US)
+1 848 304 1027
niaa@novonordisk.com |
|
|
Investors: |
|
Daniel Muusmann Bohsen
+45 3075 2175
dabo@novonordisk.com |
Jacob Martin Wiborg Rode
+45 3075 5956
jrde@novonordisk.com |
|
|
David Heiberg Landsted
+45 3077 6915
dhel@novonordisk.com |
Mark Joseph Root (US)
+1 848 213 3219
mjhr@novonordisk.com |
Novo Nordisk A/S
Investor Relations |
Novo Allé
2880 Bagsværd
Denmark |
Telephone:
+45 4444 8888 |
Internet: www.novonordisk.com CVR no:
24 25 67 90 |
|
|
Company announcement No 90 / 2022 |
SIGNATURES
Pursuant to the requirements of the
Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf of the undersigned, thereunto duly
authorized.
Date: December 19, 2022 |
NOVO NORDISK A/S
Lars Fruergaard Jørgensen
Chief Executive Officer |
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Jul 2024 to Aug 2024
Novo Nordisk (PK) (USOTC:NONOF)
Historical Stock Chart
From Aug 2023 to Aug 2024